AR170 / Y-Biologics - LARVOL DELTA

AR170, a novel PD-1×VEGF×IL-2v tri-specific immunocytokine, exploits VEGF-enriched tumor microenvironments to elicit robust and durable antitumor immunity (SITC 2026) - No abstract available

Biomarker • Trispecific • Tumor microenvironment • Oncology • PD-1

AR170, a novel PD-1xVEGFxIL-2v tri-specific immunocytokine to redefine next generation cancer immunotherapy (AACR 2026) - "Immune cell profiling showed elevated proportion of TCF1⁺PD-1⁺CD8⁺ T cells following AR170 treatment. AR170 demonstrated favorable safety and pharmacokinetic profiles in both mice and cynomolgus monkeys.ConclusionsAR170 is a next-generation cancer immunotherapy that uses a novel IL-2v fusion approach to surpass the efficacy limitations of PD-1xVEGF bispecific antibodies."

Trispecific • Oncology • CD8 • IL2

Y-Biologics said on the 7th that it signed a contract manufacturing and development (CDMO) deal with China’s WuXi Biologics to develop new drugs using its next-generation triple-target immuno-oncology platform, “Multi-AbKine.“ (Chosun Biz) - "Y-Biologics is currently developing three pipelines in parallel based on the Multi-AbKine platform. Among them, 'AR170' is being prepared for submission of an investigational new drug (IND) application for global clinical trials, including in the United States, in the first half of 2027, and 'AR166' in the second half of 2027."

IND • Licensing / partnership • Oncology